Cargando…

Intravesical ALT-803 and BCG Treatment Reduces Tumor Burden in a Carcinogen Induced Bladder Cancer Rat Model; a Role for Cytokine Production and NK Cell Expansion

Intravesical Bacillus Calmette-Guérin (BCG) has been shown to induce a specific immunologic response (i.e., activation of IL-2 and effector T-cells), while preclinical studies using ALT-803 (mutated IL-15 analogue combined with IL-15Rα-Fc fusion) have shown promising results by prolonging the agent&...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gomes-Giacoia, Evan, Miyake, Makito, Goodison, Steve, Sriharan, Aravindhan, Zhang, Ge, You, Lijing, Egan, Jack O., Rhode, Peter R., Parker, Alexander S., Chai, Karl X., Wong, Hing C., Rosser, Charles J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4045574/ https://www.ncbi.nlm.nih.gov/pubmed/24896845 http://dx.doi.org/10.1371/journal.pone.0096705

Ejemplares similares

Intravesical ALT-803 for BCG-unresponsive Bladder Cancer – A Case Report
por: Huang, Jeffrey, et al.
Publicado: (2017)

CITN-06: a Phase I/expansion trial of alt-803, an IL-15 superagonist, in patients with advanced melanoma
por: Margolin, Kim, et al.
Publicado: (2014)

The IL-15 superagonist ALT-803 enhances anti-CD20 antibody-directed NK cell ADCC and in vivo clearance of B cell lymphomas
por: Rosario, Maximillian, et al.
Publicado: (2014)

Enhanced efficacy of IL-15-based ALT-803 superagonist complex in combination with immune checkpoint inhibitors in hematologic and metastatic mouse tumor models
por: Xu, Wenxin, et al.
Publicado: (2014)

The IL-15-based superagonist ALT-803 promotes the antigen-independent conversion of memory CD8(+) T cells into innate-like effector cells with antitumor activity
por: Wong, Hing C, et al.
Publicado: (2013)

Effectiveness of two different dose administration regimens of an IL-15 superagonist complex (ALT-803) in an orthotopic bladder cancer mouse model
por: Furuya, Hideki, et al.
Publicado: (2019)

Enhanced efficacy of ALT-803, an IL-15-based superagonist complex, in combination with immune checkpoint inhibitors in an orthotopic muscle invasive bladder tumor model in mice
por: Xu, Wenxin, et al.
Publicado: (2015)

Erythropoietin is a JAK2 and ERK1/2 effector that can promote renal tumor cell proliferation under hypoxic conditions
por: Miyake, Makito, et al.
Publicado: (2013)

Influencing factors on the NMP-22 urine assay: an experimental model
por: Miyake, Makito, et al.
Publicado: (2012)

Application of a multiplex urinalysis test for the prediction of intravesical BCG treatment response: A pilot study
por: Murakami, Kaoru, et al.
Publicado: (2022)

Validation and clinicopathologic associations of a urine-based bladder cancer biomarker signature
por: Zhang, Ge, et al.
Publicado: (2014)

Combination therapy of an IL-15 superagonist complex, ALT-803, and a tumor targeting monoclonal antibody promotes direct antitumor activity and protective vaccinal effect in a syngenic mouse melanoma model
por: Chen, Xiaoyue, et al.
Publicado: (2015)

Cooperative therapeutic anti-tumor effect of IL-15 agonist ALT-803 and co-targeting soluble NKG2D ligand sMIC
por: Basher, Fahmin, et al.
Publicado: (2015)

Chemokine (C-X-C) ligand 1 (CXCL1) protein expression is increased in aggressive bladder cancers
por: Miyake, Makito, et al.
Publicado: (2013)

ALT-803 in the treatment of non-muscle-invasive bladder cancer: Preclinical and clinical evidence and translational potential
por: Chen, Wujun, et al.
Publicado: (2022)

Pott's disease post intravesical BCG
por: Jain, Anika
Publicado: (2023)

Investigation of CCL18 and A1AT as potential urinary biomarkers for bladder cancer detection
por: Miyake, Makito, et al.
Publicado: (2013)

Systemic BCG‐osis following intravesical BCG instillation for bladder carcinoma
por: Liaw, Frank, et al.
Publicado: (2017)

An IL-15 Superagonist, ALT-803, Enhances Antibody-Dependent Cell-Mediated Cytotoxicity Elicited by the Monoclonal Antibody NEO-201 Against Human Carcinoma Cells
por: Fantini, Massimo, et al.
Publicado: (2019)

The use of intravesical BCG in urothelial carcinoma of the bladder
por: Alhunaidi, Omar, et al.
Publicado: (2019)

Combinatorial therapy with an IL-15 superagonist (ALT-803) and anti-PD-L1 mAb augment T cell mediated anti-tumor immunity in mice
por: Johnson, Christopher B, et al.
Publicado: (2014)

Challenges to Improve the Stability and Efficacy of an Intravesical BCG Product
por: Hozouri, Hamidreza, et al.
Publicado: (2014)

Disseminated BCG: Complications of Intravesical Bladder Cancer Treatment
por: To, Uyen, et al.
Publicado: (2014)

Protective role of intravesical BCG in COVID-19 severity
por: Gallegos, Héctor, et al.
Publicado: (2021)

An uncommon cause of miliary disease: intravesical BCG immunotherapy
por: Azevedo, Marcelo, et al.
Publicado: (2021)

Matrix metalloproteinase-10 promotes tumor progression through regulation of angiogenic and apoptotic pathways in cervical tumors
por: Zhang, Ge, et al.
Publicado: (2014)

Simultaneous multi-analyte urinary protein assay for bladder cancer detection
por: Rosser, Charles J, et al.
Publicado: (2014)

IL15N72D superagonist/IL15Rα-Fc fusion complex (ALT-803) exhibits anti-metastatic activity in murine breast tumor model
por: Kim, Peter S, et al.
Publicado: (2015)

Safety, Tolerability, and Long-Term Clinical Outcomes of an IL-15 analogue (N-803) Admixed with Bacillus Calmette-Guérin (BCG) for the Treatment of Bladder Cancer
por: Rosser, Charles J., et al.
Publicado: (2021)

Autophagy Controls BCG-Induced Trained Immunity and the Response to Intravesical BCG Therapy for Bladder Cancer
por: Buffen, Kathrin, et al.
Publicado: (2014)

Asymptomatic renal BCG granulomatosis: An unusual complication of intravesical BCG therapy for carcinoma urinary bladder
por: Bhat, Suresh, et al.
Publicado: (2015)

Case Presentation: Lung Consolidation as Sequelae of BCG Sepsis After Combined Intravesical and Intraurethral BCG
por: Strich, Jeffrey R., et al.
Publicado: (2017)

Oktett, D. 803
por: Schubert, Franz, 1797-1828
Publicado: (1988)

BCGitis: A rare complication after intravesical BCG therapy
por: Oliveira, Maria João, et al.
Publicado: (2015)

Bladder Sparing Therapy for BCG Failures – I – Intravesical Immunotherapy
por: Messing, Edward M.
Publicado: (2017)

Mycobacteria Bovis osteomyelitis following intravesical BCG for bladder cancer
por: Seegobin, Karan, et al.
Publicado: (2017)

Reactive Arthritis – A Rare Complication of Intravesical BCG Instillation
por: Freixa, Marta, et al.
Publicado: (2020)

Systemic BCG-Osis as a Rare Side Effect of Intravesical BCG Treatment for Superficial Bladder Cancer
por: Lukacs, S., et al.
Publicado: (2013)

Schedule of experiment R803
por: Jarlskog, G
Publicado: (1973)

Discriminators of mouse bladder response to intravesical Bacillus Calmette-Guerin (BCG)
por: Saban, Marcia R, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_amoil739bgc334jfumr9s517n9